Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy

BACKGROUND: TP53 mutations are frequent in breast cancer, however their clinical relevance in terms of response to chemotherapy is controversial. METHODS: 450 pre-therapeutic, formalin-fixed, paraffin-embedded core biopsies from the phase II neoadjuvant GeparSixto trial that included HER2-positive a...

Descripción completa

Detalles Bibliográficos
Autores principales: Darb-Esfahani, Silvia, Denkert, Carsten, Stenzinger, Albrecht, Salat, Christoph, Sinn, Bruno, Schem, Christian, Endris, Volker, Klare, Peter, Schmitt, Wolfgang, Blohmer, Jens-Uwe, Weichert, Wilko, Möbs, Markus, Tesch, Hans, Kümmel, Sherko, Sinn, Peter, Jackisch, Christian, Dietel, Manfred, Reimer, Toralf, Loi, Sherene, Untch, Michael, von Minckwitz, Gunter, Nekljudova, Valentina, Loibl, Sibylle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Priority Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5356512/
https://www.ncbi.nlm.nih.gov/pubmed/27611952
http://dx.doi.org/10.18632/oncotarget.11891

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5356512/
https://www.ncbi.nlm.nih.gov/pubmed/27611952
http://dx.doi.org/10.18632/oncotarget.11891

Ejemplares similares